Literature DB >> 18204256

Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia.

Shigehiko Fujii1, Daisuke Katsumata, Takahiro Fujimori.   

Abstract

The incidence of colorectal neoplasia has been increasing among patients with long-standing and extensive ulcerative colitis (UC), and therefore surveillance colonoscopy has been widely recommended. However, because UC-associated neoplasia is often difficult to detect endoscopically and to discriminate from inflammatory regenerative epithelium histologically, the efficacy of current surveillance remains unsatisfactory. In order to overcome these difficulties, adjunctive modalities for diagnosing UC-associated neoplasia, chromo- and magnifying endoscopy for endoscopic diagnosis and analysis of p53 alteration for histological diagnosis have been introduced. Furthermore, if it were possible to differentiate UC patients with long-standing and extensive colitis into subgroups with a high and a low risk of neoplasia, it would enable physicians to conduct more intensive surveillance with these modalities for patients at higher risk. Several molecular alterations of nonneoplastic epithelium in UC patients with neoplasia may be promising as markers for identifying individuals with UC at increased risk of neoplasia. We evaluated estrogen receptor (ER) methylation of nonneoplastic colorectal epithelium to clarify whether this epigenetic alteration can contribute to the prediction of increased neoplasia risk in UC patients and demonstrated that the ER methylation level in nonneoplastic epithelium was higher throughout the colorectum in patients with neoplasia than in those without. These results suggest that analysis of ER gene methylation may be potentially useful for identifying individuals at increased risk of neoplasia among patients with long-standing and extensive UC. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204256     DOI: 10.1159/000111482

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  12 in total

1.  p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia.

Authors:  Hala E Hamouda; Soha S Zakaria; Saber A Ismail; Mahmoud A Khedr; Wael W Mayah
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 2.  Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.

Authors:  Sigrun Thorsteinsdottir; Thorkell Gudjonsson; Ole Haagen Nielsen; Ben Vainer; Jakob Benedict Seidelin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

3.  Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia.

Authors:  Rajan K Bista; Teresa A Brentnall; Mary P Bronner; Christopher J Langmead; Randall E Brand; Yang Liu
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

4.  Relationship between methylation and colonic inflammation in inflammatory bowel disease.

Authors:  Triana Lobatón; Daniel Azuara; Francisco Rodríguez-Moranta; Carolina Loayza; Xavier Sanjuan; Javier de Oca; Ana Fernández-Robles; Jordi Guardiola; Gabriel Capellá
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 5.  Indications, stains and techniques in chromoendoscopy.

Authors:  P J Trivedi; B Braden
Journal:  QJM       Date:  2012-10-24

6.  Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein.

Authors:  Wan-Yee Tang; Retha Newbold; Katerina Mardilovich; Wendy Jefferson; Robert Y S Cheng; Mario Medvedovic; Shuk-Mei Ho
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

7.  Immunohistochemical analysis of the DNA methyltransferase 3b expression is associated with significant improvements in the discrimination of ulcerative colitis-associated neoplastic lesions.

Authors:  Hirofumi Ueda; Hiroyuki Tanaka; Kazuhito Ichikawa; Michio Itabashi; Shingo Kameoka; Shigehiko Fujii; Natsuko Saito; Ryusuke Kimura; Yosuke Shida; Yukari Fujimori; Shinichirou Ohtake; Shigeki Tomita; Johji Imura; Yoshikazu Yasuda; Nobuhiko Tanigawa; Kazuhisa Uchiyama; Takahiro Fujimori
Journal:  Surg Today       Date:  2013-01-10       Impact factor: 2.549

8.  Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry.

Authors:  Kayo Horie; Tetuo Mikami; Tsutomu Yoshida; Yuichi Sato; Isao Okayasu
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

9.  High expression of HSP47 in ulcerative colitis-associated carcinomas: proteomic approach.

Authors:  K Araki; T Mikami; T Yoshida; M Kikuchi; Y Sato; M Oh-ishi; Y Kodera; T Maeda; I Okayasu
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Immunohistochemical assessment of a unique basal pattern of p53 expression in ulcerative-colitis-associated neoplasia using computer-assisted cytometry.

Authors:  Shunsuke Kobayashi; Takahiro Fujimori; Hiroyuki Mitomi; Shigeki Tomita; Kazuhito Ichikawa; Johji Imura; Shigehiko Fujii; Michihiro Itabashi; Shingo Kameoka; Yoshinori Igarashi
Journal:  Diagn Pathol       Date:  2014-05-29       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.